Aptose Biosciences (NASDAQ:APTO) PT Set at $4.00 by HC Wainwright

HC Wainwright set a $4.00 target price on Aptose Biosciences (NASDAQ:APTO) (TSE:APS) in a report issued on Wednesday, November 15th. The brokerage currently has a buy rating on the biotechnology company’s stock.

A number of other brokerages have also weighed in on APTO. ValuEngine raised Aptose Biosciences from a strong sell rating to a sell rating in a research report on Tuesday, October 31st. Zacks Investment Research upgraded Aptose Biosciences from a hold rating to a buy rating and set a $1.50 price target for the company in a report on Monday, August 14th. Finally, Roth Capital reiterated a buy rating and set a $5.00 price target on shares of Aptose Biosciences in a report on Monday, October 23rd. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and four have assigned a buy rating to the company’s stock. The company has a consensus rating of Buy and an average target price of $4.50.

Aptose Biosciences (NASDAQ:APTO) opened at $2.01 on Wednesday. Aptose Biosciences has a 12 month low of $0.78 and a 12 month high of $2.30.

COPYRIGHT VIOLATION WARNING: This piece was reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this piece on another domain, it was illegally copied and republished in violation of US and international copyright and trademark legislation. The correct version of this piece can be read at https://www.dispatchtribunal.com/2017/12/02/aptose-biosciences-inc-apto-given-a-4-00-price-target-by-hc-wainwright-analysts-2.html.

About Aptose Biosciences

Aptose Biosciences Inc (Aptose) is a clinical-stage biotechnology company. The Company is engaged in the development of anticancer drugs that target specific epigenetic processes and signal transduction abnormalities that underlie a particular life-threatening malignancy. Its product pipeline includes cancer drug candidates that exert activity as stand-alone agents and that enhance the activities of other anticancer agents without causing overlapping toxicities.

Receive News & Ratings for Aptose Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptose Biosciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply